Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
Mathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, Alex Friedlaender
Abstract
are discussed, as well as agents targeting these alterations. Current standards of treatment as well as promising future strategies are presented. Currently, more than fifteen targeted agents are food and Drug administration-approved for seven oncogenic drivers in non-small-cell lung cancer, highlighting the importance of actively searching for these mutations. Continuous and future efforts made in defining the biology of each of these alterations will help to elucidate their respective resistance mechanisms, and to define the best treatment strategy and therapeutic sequence.
Topics & Concepts
Anaplastic lymphoma kinaseCancer researchCarcinogenesisEpidermal growth factor receptorLung cancerCancerMedicineErbBReceptor tyrosine kinaseViral OncogeneTargeted therapyOncogeneTyrosine kinaseBiologyKinaseOncologyCell cycleInternal medicineReceptorGeneticsMalignant pleural effusionLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancerCancer Mechanisms and Therapy